Intermediate modular molecules for activating chimeric antigen receptor effector cells and uses thereof
By developing an intermediate module molecular system containing targeting peptides and exogenous tag molecules, the problems of antigen deficiency and tolerance of chimeric antigen receptor T cells in the treatment of solid tumors have been solved, enabling effective targeting and killing of various cancers, reducing side effects, and enhancing therapeutic efficacy.
Patent Information
- Application Number
- CN202310611843.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2026-07-24
- Estimated Expiration
- 2043-05-24
AI Technical Summary
Existing chimeric antigen receptor T cells face challenges in treating solid tumors, including antigen deficiency or lack of target expression due to tumor heterogeneity, tolerance caused by tumor evolution, and severe side effects caused by continuous activation, which limit their application in solid tumors.
Develop an intermediate module molecular system comprising a targeting peptide, an exogenous tag molecule, and a linker to activate chimeric antigen receptor effector cells and achieve translatable targeting and killing effects by binding to CD44, EpCAM, or GPC3 tumor-associated antigens.
When antigens are mutated or lost, the intermediate module molecular system can effectively regulate the activity of chimeric antigen receptor T cells, improve the efficacy of treating various cancers, reduce side effects, enhance the ability to target tumors and T cell infiltration, and overcome tolerance to CAR-T therapy.